Anna Chaimani from the COVID-NMA team has asked me to help identify clinicians with experience of treating COVID, in order to help the team construct their network meta-analyses. The principle questions surround which drug classes to include in the same NMA, where the transitivity assumption is likely to be valid. If you have this experience, or know people who do, please could you either complete the survey at the link below or forward the link to a colleague as appropriate.

email Anna here